Inogen Inc (NASDAQ:INGN), a medical technology company, reported fourth-quarter 2023 revenues of $75.90 million, missing the consensus of $76.99 million. Fourth quarter total revenue fell from $88.1 million in the fourth quarter of 2022. This was primarily due to a decrease in domestic business-to-business and direct-to-consumer sales, partially offset by higher rental revenue. Inogen reported an adjusted EPS loss of $(0.83). While the company missed the consensus of $(0.62), it reported higher than the $(0.57) reported a year ago. Also Read: Competitor Exit A Boom For Respiratory Device-Focus…